Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib topical - Promius Pharma

Next Previous
Drug Profile

Celecoxib topical - Promius Pharma

Alternative Names: DFD-07

Latest Information Update: 11 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Promius Pharma
  • Class Antimigraines; Antineoplastics; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Actinic keratosis

Most Recent Events

  • 27 Oct 2020 Clinical development for Actinic keratosis (In adults) is still ongoing in USA (NCT03116698)
  • 27 Oct 2020 No development reported - Phase-II for Actinic keratosis (In the elderly, In adults) in Germany (Topical)
  • 05 Jul 2018 Dr. Reddy's Laboratories Limited completes a phase II/III trial in Actinic keratosis (In adults) in USA (Topical) (NCT03116698)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top